When credibility is critical, choose a partner that inspires confidence.

When complex financial problems arise, Gleason Experts helps clients minimize risk exposure, consider alternative scenarios, project results and take advantage of strategic opportunities.

Gleason IP takes a client-focused, cost-effective approach to IP issues, delivering insightful economic and financial analyses across a range of industries, with particular knowledge/expertise in Pharma/Life Sciences.

Gleason Trust has decades of experience in trust accounting, trust management and administration, and providing high-quality service to meet the fiduciary needs of a variety of trusts.

Gleason Advisors provides valuable financial and strategic advice to closely held, private companies throughout the business life cycle. Our experience spans multiple industries and challenges.


Value Beyond Dispute

Gleason is committed to providing honest, independent, objective opinions on financial and economic issues, supported by thoughtful, thorough analysis and relevant, reliable data. Our unmatched experience and integrity repeatedly produce results that withstand detailed – and often ruthless – examination.
Since 1988, our clients have found exceptional value in our insights. We are a trusted and proven partner in disputed, high risk scenarios that require specialized valuation and financial analysis.
Thousands of clients across the nation rely on our proficiency in accounting, tax, finance and economics. Our seasoned professionals hold credentials including CPA, CFA, CFE and MBA, and their expertise is widely recognized.

News and Press

Gleason IP News & Updates

April 22, 2024

Recent Changes to the Federal Rules of Evidence Governing the Admissibility of Expert Testimony Effective December 1, 2023, the Federal Rules of Evidence relating to the admissibility of expert testimony were amended. The Federal Advisory Committee on Evidence Rules (the “Committee”) indicated that Rule 702 (Testimony by Expert Witness) was amended in order to clarify...   Read More

Gleason IP News & Updates

January 19, 2024

Federal Circuit Affirms Use of Skinny Label for Vortioxetine   In December 2023, the United States Court of Appeals for the Federal Circuit affirmed a district court’s opinion regarding noninfringement of two patents related to specific uses of the antidepressant drug Trintellix® (vortioxetine).  This opinion reaffirmed the use of the “section viii” statement, allowing companies...   Read More

Find out about Careers at Gleason

We’re always on the lookout for talented new additions to the Gleason team.

Learn More